Alixia Analysis: $2M Raised
What is Alixia?
Alixia targets cancer drug resistance by studying tumor ecosystems and developing therapies that disrupt metabolic and inflammatory triggers in cancer cells.
Founded
2022
Revenue
$1M
Company Stage
Seed
YC Batch
W22
Product Features & Capabilities
- tumor ecosystem disruptors, compounds targeting metabolic and inflammatory triggers, therapeutic portfolio addressing cancer, aging, neurodegeneration, inflammation, immune dysregulation
How much Alixia raised
1 - $1,825,445
July 23, 2024Lead Investor: Not specified
Who are the founders of Alixia
OM
Olof Mollstedt
Co-founder & Co-CEO
HC
Helen Chen, Ph.D.
Co-founder & Co-CEO
Investors
- Y Combinator
- IndieBio
- Eight Capital
- Endless Frontier Labs
- MCMA Ventures
- Gaingels
